欧林生物9月29日大宗交易平台共发生3笔成交，合计成交量120.19万股，成交金额2558.40万元。以折溢 价进行统计，今日3笔大宗交易成交价相对收盘价均为折价交易。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为5535.07万元。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日，注册资本40593.36万人民 币。（数据宝） 证券时报·数据宝统计显示，欧林生物今日收盘价为26.68元，上涨4.63%，日换手率为1.62%，成交额为 1.74亿元，全天主力资金净流出427.42万元，近5日该股累计下跌2.56%，近5日资金合计净流入119.35万 元。 两融数据显示，该股最新融资余额为3.11亿元，近5日减少1933.07万元，降幅为5.85%。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 45.00 | 1017.00 | 22 ...

9月29日，欧林生物大宗交易成交120.19万股，成交额2558.4万元，占当日总成交额的12.83%，成交均 价21.29元，较市场收盘价26.68元折价20.22%，其中最高成交价22.6元，最低成交价20.5元。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) | | 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-29 | 欧林生物 | 688319 | 22.6 | 1017 | 45 | 2017 11:52 | 全面度最高出货器 | 140 | | 2025-09-29 | 欧林生物 | 612899 | 20.5 | 881.5 | 43 | 容自身有人民常落 | 不會議是大賞為醫 | KI | | 2025-09-29 | 欧林生物 | 688319 | 20.5 | 659.9 | 32.19 | 茶量度發展開發 | 不動量發送與點點 | Ka | ...

Group 1 - The core point of the article highlights the recent performance of Olin Biological, which saw a 5.1% increase in stock price, reaching 26.80 yuan per share, with a total market capitalization of 10.879 billion yuan [1] - Olin Biological, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Biological is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a floating profit of approximately 22,400 yuan from this investment, with a total fund size of 11.8186 million yuan [2] - Year-to-date, the fund has achieved a return of 14.22%, with a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]

欧林生物9月24日大宗交易平台出现一笔成交，成交量16.00万股，成交金额358.56万元，大宗交易成交 价为22.41元，相对今日收盘价折价16.32%。该笔交易的买方营业部为机构专用，卖方营业部为广发证 券股份有限公司成都麓山大道证券营业部。 进一步统计，近3个月内该股累计发生8笔大宗交易，合计成交金额为2976.67万元。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日。注册资本40593.36万人民 币。（数据宝） 9月24日欧林生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 16.00 | 358.56 | 22.41 | -16.32 | 机构专 | 广发证券股份有限公司成都麓山 | | | | | | 用 | 大道证券营业部 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，欧林生物今日 ...

Core Viewpoint - Oulin Bio is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure, following the termination of its previous fundraising plan [1][2][3]. Group 1: H-Share Listing Plans - Oulin Bio is currently in discussions with relevant intermediaries regarding the H-share listing, with specific details yet to be determined [1][2]. - The H-share listing will require approval from the company's board, shareholders, and various regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]. Group 2: Termination of Previous Fundraising - The company recently terminated a year-long plan for a private placement that aimed to raise 1.25 billion yuan for the renovation of its vaccine R&D production base [3]. - The initial private placement plan was announced in June of the previous year, with a target of 1.75 billion yuan, but was later reduced due to market conditions [3]. Group 3: Financial Performance - In the first half of the year, Oulin Bio achieved a revenue of 306 million yuan, a year-on-year increase of 35.17%, and a net profit of 13.2 million yuan, marking a return to profitability [4]. - The company's core product, the Tetanus Toxoid Vaccine, has shown significant revenue growth, contributing to 90.99% of total revenue in the first half of the year [4]. Group 4: R&D and Future Projects - Oulin Bio is focusing on balancing R&D investment with operational cash flow, with a total R&D expenditure of 65.25 million yuan in the first half of the year, accounting for 21.33% of revenue [5]. - The company is advancing its pipeline projects, including the recombinant Staphylococcus aureus vaccine, which is expected to complete its Phase III clinical trials by mid-2026 [4][5].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase its global visibility, and optimize its capital structure [1][2]. Group 1 - The company is currently discussing the details of the H-share listing with relevant intermediaries, and specific details have not yet been finalized [2]. - The H-share listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, the Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]. - The company will fulfill its information disclosure obligations in accordance with relevant laws and regulations as the H-share listing progresses [2].

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

★ 宏观动态 ★ 经合组织预测2025年全球经济增速为3.2%，2026年将放缓至2.9% 经济合作与发展组织（经合组织）23日发布中期经济展望报告，预计2025年全球经济增速为3.2%，较今年6月 预测值上调0.3个百分点；2026年全球经济增速将放缓至2.9%，与6月预测值相同。 陕西省省长赵刚：中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆全境 陕西省省长赵刚今日在2025欧亚经济论坛上表示，中欧班列西安集结中心已开通国际干线18条、覆盖亚欧大陆 全境，核心指标稳居全国第一，上半年开行3055列、同比增长28.8%。西安国际航空枢纽，已开通国际客运航 线60条、全货运航线16条，上半年国际航班客运量、货运量分别增长71%和124.8%。我们持续提升枢纽的承载 力、辐射力，推动港产港贸港城融合发展，引导外向度高的适铁、临空产业集聚发展。如今，中欧班列满载着 汽车、光伏、家电等"陕西制造"横贯欧亚、走向世界。 工信部：组合驾驶辅助系统乘用车新车市场渗透率超60% 香港交易所今天宣布与广州碳排放权交易中心有限公司，深圳绿色交易所， 澳门国际碳排放权交易所签署合 作备忘录，携手推动粤港澳大湾区碳市场及绿 ...

Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase global recognition, and optimize its capital structure [1] Group 1 - The company aims to deepen its international strategic layout [1] - The initiative is intended to enhance the company's international visibility and influence [1] - The move is part of efforts to strengthen the company's overall competitive strength [1]